Script Pad

2.5 mL and 5 mL volumes of Bromfenac Ophthalmic Solution 0.09% bioequivalent to XIBROM®*

Bromfenac Ophthalmic Solution is indicated for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract extraction.

  • The ONLY generic bioequivalent to XIBROM
  • The LARGEST volume (5 mL) of Ophthalmic Solution containing the active ingredient bromfenac sodium

High quality, low cost Bromfenac Ophthalmic Solution is available in two sizes:

  • 2.5 mL
  • 5 mL

Prescribe your patients Mylan's high quality, low cost Bromfenac Ophthalmic Solution as an alternative to XIBROM.

Important Safety Information

CONTRAINDICATION

Bromfenac ophthalmic solution is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS

Contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. There is a potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal anti-inflammatory drugs (NSAIDs). Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

PRECAUTIONS

All topical NSAIDs may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post surgery may increase patient risk for the occurrence and severity of corneal adverse events. It is recommended that bromfenac ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medication which may prolong bleeding time. Bromfenac ophthalmic solution should not be administered while wearing contact lenses.

ADVERSE REACTIONS

The most commonly reported adverse experiences reported following use of bromfenac ophthalmic solution after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache, and iritis. These events were reported in 2% to 7% of patients.

Click here for full Prescribing Information.

Discover why, at Mylan, quality isn't just a claim - it's a cause we've made personal.

For more information, please call Customer Relations at 1.800.796.9526.